Factor XI Inhibition: Adult Evidence and Paediatric Considerations.

Factor XI (FXI) inhibition represents an innovative approach to anticoagulation, offering the potential for effective thromboprophylaxis with a reduced risk of bleeding. While intensive clinical research is underway in adult populations, its relevance to the treatment of children remains largely unknown. The evidence base to inform potential paediatric use is still limited, and the extent to which findings from adult studies can be translated to paediatric care has yet to be clarified. This review systematically maps the existing evidence from preclinical and adult studies on FXIa and examines its implications for future paediatric application and treatment strategies.